141411-00-9

Basic information

• Product Name: [1R-[1alpha(S*),3abeta,7aalpha]]-1-[2-(Acetyloxy)-1-methylethyl]octahydro-7a-methyl-4H-inden-4-one
• Synonyms: (S)-2-((1R,3aR,7aR)-7a-Methyl-4-oxooctahydro-1H-inden-1-yl)propyl acetate;[1R-[1alpha(S*),3abeta,7aalpha]]-1-[2-(Acetyloxy)-1-methylethyl]octahydro-7a-methyl-4H-inden-4-one
• CAS NO: 141411-00-9
• Molecular Formula: C₁₅H₂₄O₃
• Molecular Weight: 252.34926
• Mol File: 141411-00-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.049
• CAS DataBase Reference: [1R-[1alpha(S*),3abeta,7aalpha]]-1-[2-(Acetyloxy)-1-methylethyl]octahydro-7a-methyl-4H-inden-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: [1R-[1alpha(S*),3abeta,7aalpha]]-1-[2-(Acetyloxy)-1-methylethyl]octahydro-7a-methyl-4H-inden-4-one(141411-00-9)
• EPA Substance Registry System: [1R-[1alpha(S*),3abeta,7aalpha]]-1-[2-(Acetyloxy)-1-methylethyl]octahydro-7a-methyl-4H-inden-4-one(141411-00-9)

Safety Data

• Hazardous Substances Data: 141411-00-9(Hazardous Substances Data)

Usage

General Description

The chemical compound "[1R-[1alpha(S*),3abeta,7aalpha]]-1-[2-(Acetyloxy)-1-methylethyl]octahydro-7a-methyl-4H-inden-4-one" is a complex organic compound with a long and complicated name. It is a type of ketone that contains a cyclohexane ring and a side chain with an acetyloxy group. The compound has a chiral center and is also a stereoisomer, indicating the different spatial arrangements of atoms. It is often used in the field of organic chemistry and pharmaceutical research due to its unique structure and properties.

Upstream product

• 64190-52-9 (8S,20S)-de-A,B-20-(hydroxymethyl)pregnan-8-ol 
• 108-24-7 acetic anhydride 
• 141245-56-9 (20S)-Des-A,B-22-(acetoxy)-23,24-dinorcholane-8β-ol 

Downstream Products

• 87407-53-2 22-hydroxyhomopregnacalciferol 
• 1258066-55-5 AB₄₇ 
• 142777-79-5 (S)-4-Benzenesulfonyl-2-{(1R,3aS,7aR)-4-[2-[(3R,5R)-3,5-bis-(tert-butyl-dimethyl-silanyloxy)-cyclohexylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-8-ethyl-8-triethylsilanyloxy-decan-3-ol 
• 142777-80-8 (1R,3aS,7aR)-4-[2-[(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-cyclohexylidene]-eth-(E)-ylidene]-1-((E)-(R)-7-ethyl-1-methyl-7-triethylsilanyloxy-non-2-enyl)-7a-methyl-octahydro-indene 
• 142777-77-3 (E)-(1R,3R,20S)-1,3-Bis-(tert-butyl-dimethyl-silanyloxy)-20-methyl-19-nor-9,10-seco-pregna-5,7-dien-21-ol 
• 142777-81-9 Δ²²,22E,19-nor-24,24-dihomo-26,27-dihomo-1α,25-dihydroxyvitamin D3 
• 142777-78-4 (S)-2-((1R,3aS,7aR,E)-4-(2-((3R,5R)-3,5-bis(tertbutyldimethylsilyloxy)cyclohexylidene)ethylidene)-7a-methyloctahydro-1H-inden-1-yl)propanal 
• 141404-12-8 Acetic acid (S)-2-{(1R,3aS,7aR)-4-[2-[(3R,5R)-3,5-bis-(tert-butyl-dimethyl-silanyloxy)-cyclohexylidene]-eth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-propyl ester 

Relevant articles and documents

2-Methylene-(22E)-25-Hexanoyl-24-OXO-26,27-Cyclo-22-Dehydro-19-Nor-Vitamin D Analogs

This invention discloses 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-hexanoyl-24-oxo-26,27-cyclo-22-dehydro-19-nor-1α-hydroxyvitamin D3, and pharmaceutical uses therefor. This compound exhibits relatively high transcription activity as well as pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also shows low activity in vivo on bone calcium mobilization, and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

22-HALOACETOXY-HOMOPREGNACALCIFEROL ANALOGS AND THEIR USES

This invention discloses 22-haloacetoxy-homopregnacalciferol analogs and specifically 22-bromoacetoxy-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits relatively little calcemic activity and does not promote cellular different

1α-Hydroxy-19-nor-vitamin D C-22 aldehyde. A valuable intermediate in the synthesis of side chain modifed 1α,25-dihydroxy-19-nor-vitamin D3

A side chain homologated 1α,25-dihydroxy-19-nor-vitamin D3 analog was prepared in a double convergent synthesis with 1α-hydroxy-19-nor-vitamin D C-22 aldehyde as a key intermediate.